In May 2018, the Moscow Endocrine Plant celebrated its 75th anniversary. Today, the enterprise has a strong position in the Russian pharmaceutical market and manufactures a wide range of socially important medicines, most of which are the vital and essential drugs.
Speaking at the official ceremony to award employees of the plant, Sergey Tsyb, First Deputy Minister of Industry and Trade of the Russian Federation, said,
“We set the objective to make the Moscow Endocrine Plant a Leader of Russian pharmaceutical industry, and I think that we will achieve it. The plant already demonstrates very effective results, as its product portfolio includes about 90 drugs, and more than 50 medicines are in the list of vital and essential drugs. The manufacturing involves virtually all finished dosage forms currently produced in the Russian Federation, such as ampoules, vials, tablets and capsules, minimally invasive forms, and other.”
In April 2018, Lefortovsky branch (Moscow) was established on the premises of the former GosZMP, a federal state unitary enterprise. New site will allow to diversify the production capacities of the plant and establish laboratories for modeling new medicinal products. The issue of establishing a branch of the Moscow Endocrine Plant in the Bryansk region to manufacture active pharmaceutical substances from raw materials of plant and animal origin, as well as substances obtained by chemical synthesis, is currently under consideration. Today, the enterprise employs more than 1000 people.